https://www.imosver.com/en/libros/malignant-lymphomas-including-hodgkins-disease-diagnosis-management-and-special-problems-00106323330010632333Malignant lymphomas, including Hodgkin?s disease: Diagnosis, management, and special problems148.19This volume is intended to present an eclectic selection of informative reviews on aspects of the malignant lymphomas, including Hodgkin's disease. The choice of suitable review topics in this field ihttps://static.imosver.com/imagenes_small/9781461/978146136347.jpgLibrosSin stockSPRINGER000https://static.imosver.com/imagenes_small/9781461/978146136347.jpg0010749495001074949600107307340010749494155.9957.82012/09/249781461363477VV.AA.Librosaño_2012idioma_EnglishIautor_VV.AA.saga_Cancer Treatment and Research
Artículo
Malignant lymphomas, incl
VV.AA.
SPRINGER
Cookie notice
We use cookies to ensure you get the best experience on our site
Read cookie policy.
Manage cookie preferences
This type of cookie allows the user to browse a website, platform, or application and to use the different options or services that exist on it.
imosver_session
Description
Essential first-party cookie. It keeps your session identified while you browse: your basket, your language and access to your account. The website cannot work without it.
Duration
120 minutes
Facilities
Domain
imosver.com
OCT8NE
Description
This cookie is used for the proper functioning of the Oct8ne Chat to provide customer support service to the user.
These are those that enable the tracking and analysis of user behavior on our website. The information collected is used to measure user activity on the website and to create user browsing profiles.
_clsk
Description
Microsoft Clarity first-party cookie. It groups the pages you visit into a single session in order to analyse your journey through the website.
Duration
1 days
Facilities
Domain
imosver.com
logglytrackingsession
Description
Identifies and records the user session for analytical purposes.
Duration
Session
Facilities
Domain
.imosver.com
GOOGLE_ANALYTICS
Description
Records a unique identifier that is used to generate statistical data about how the visitor uses the website.
Duration
1 Year
Facilities
Domain
.imosver.com
_clck
Description
Microsoft Clarity first-party cookie. It stores an anonymous browser identifier so that visits to this website can be attributed to the same user and usage statistics can be produced.
Duration
1 Year
Facilities
Domain
imosver.com
CLID
Description
Microsoft Clarity third-party cookie. It identifies the first time Clarity detects this browser on any website using the service.
Duration
1 Year
Facilities
Domain
clarity.ms
_ga
Description
Google Analytics cookie. It stores an anonymous browser identifier in order to distinguish users and produce website usage statistics.
Duration
2 Year
Facilities
Domain
.imosver.com
_ga_LZR660YW0M
Description
Google Analytics 4 cookie. It keeps the analytics session state so that visits and the journey through the website can be measured.
Duration
2 Year
Facilities
Domain
.imosver.com
These are the ones that allow us to adapt the navigation on our website to your preferences (e.g., language, browser used, etc.).
_fbp
Description
Used by Facebook to offer a series of advertising products, such as real-time bids from third-party advertisers.
Duration
3 Month
Facilities
Domain
.imosver.com
afiliado
Description
First-party affiliate programme cookie. It stores for 30 days the code of the affiliate that brought you to the website, so that the sale can be attributed to them.
Duration
1 Month
Facilities
Domain
imosver.com
MUID
Description
Microsoft third-party cookie. It identifies unique browsers visiting Microsoft sites and is used for advertising, analytics and other operational purposes.
Duration
1 Year
Facilities
Domain
clarity.ms
ANONCHK
Description
Microsoft third-party cookie. It indicates whether the MUID identifier is transferred to ANID, a cookie used for advertising purposes.
Duration
10 minutes
Facilities
Domain
clarity.ms
MR
Description
Microsoft third-party cookie. It indicates whether the MUID identifier must be refreshed.
Duration
7 days
Facilities
Domain
clarity.ms
SM
Description
Microsoft third-party cookie. It synchronises the MUID identifier across Microsoft domains.
Duration
Session
Facilities
Domain
clarity.ms
_fbc
Description
Meta cookie. It stores the identifier of the Facebook or Instagram advert you arrived from, in order to attribute the visit to that advertising campaign.
Duration
3 Month
Facilities
Domain
.imosver.com
_gcl_au
Description
Google Ads cookie. It records a visit coming from an advert so that advertising campaign conversions can be measured.
Duration
3 Month
Facilities
Domain
.imosver.com
_uetsid
Description
Microsoft Advertising cookie. It identifies your browsing session in order to measure conversions from Bing advertising campaigns.
Duration
1 days
Facilities
Domain
.imosver.com
_uetvid
Description
Microsoft Advertising cookie. It identifies your browser across visits in order to measure conversions from Bing advertising campaigns.
Synopsis Malignant lymphomas, including Hodgkin?s disease: Diagnosis, management, and special problems
This volume is intended to present an eclectic selection of informative reviews on aspects of the malignant lymphomas, including Hodgkin's disease. The choice of suitable review topics in this field is made hazardous by several facts. First, the growth of insight into basic mechanisms of lymphomagenesis is explosive, as is the expansion of our understanding of the need for precise morphologic classification of these diseases. Second, new therapeutic agents, cytotoxic and biologic, as well as new drug delivery strategies, are appearing with remarkable frequency. Finally, old "standard" approaches, such as the staging laparotomy for Hodgkin's disease, are being reconsidered and deserve attention in an up-to-date collection of papers. The 10 reviews presented here fall generally into three categories. First, the optimal diagnostic and therapeutic approaches to Hodgkin's disease are considered by Mark Leibenhaut, who reviews the status of the diagnostic staging laparotomy, and by Philip Bierman, who discusses his thoughts on the timing of high-dose treatment with bone marrow transplantation for this disease. There follow four reviews of current management of specific histologic subtypes of malignant lymphoma. First, Velasquez reviews prognostic factors in both intermediate and high grade lymphomas. Miller and Dahlberg review and update the Southwest Oncology Group experience in developing curative cytotoxic combination therapies for diffuse large-cell lymphomas. Lastly, optimal therapy for two kinds of high grade lymphoma are presented. Butler and Hainsworth describe the Vanderbilt experience with diffuse small noncleaved cell lymphoma and Picozzi reviews lymphoblastic lymphoma.